ArticleBMC cancer2025
Comorbidity burden in elderly high-grade glioma patients: impact on radiotherapy outcomes.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundElderly high-grade glioma (HGG) or glioblastoma (GBM) patients face challenging treatment conditions due to comorbidities and age-related factors. The age-adjusted Charlson Comorbidity Index (ACCI) accounts for age and comorbidities and serves as a tool for predicting survival rates in various clinical scenarios. This study examined its prognostic value in elderly HGG patients undergoing radiotherapy (RT) and concurrent chemoradiotherapy (CRT).
methodsWe retrospectively analyzed 163 elderly HGG patients (≥ 60 years) treated with radiotherapy (RT) or chemo-RT (CRT) at TUM University Hospital (2001-2021). Kaplan-Meier analysis estimated median overall survival (OS) by ACCI group (≤ 5 vs. ≥6). Multivariate Cox regressions assessed OS and progression-free-survival (PFS) based on fractionation and treatment strategies. Further Cox models evaluated ACCI scores, age, comorbidities, and mortality. A random survival forest (RSF) identified key survival predictors, using permutation importance with bootstrapped confidence intervals.
resultsAmong the 163 HGG patients, those with greater comorbidities (ACCI ≥ 6) had a shorter median OS (14.8 months) than did those with ACCI ≤ 5 (22.6 months) (log-rank p = 0.463). In the ACCI ≤ 5 subgroup, hypofractionated RT (hRT) alone was significantly associated with worse OS than Stupp was (HR = 85.7, 95% CI: 7.1-914.3, p = 0.0004), whereas no significant differences were detected in the ACCI ≥ 6 subgroup. Hypofractionated RT was associated with improved PFS in patients with an ACCI ≥ 6 (HR = 0.47, 95% CI: 0.24-0.92, p = 0.027), and MGMT methylation better predicted OS (HR = 0.31, p = 0.0039) and PFS (HR = 0.32, p = 0.0059). Diabetes without complications independently predicted worse OS (HR = 2.91 (95% CI: 1.63-5.18, p < 0.001)) and PFS (HR = 2.59 (95% CI: 1.43-4.70, p = 0.002), with a significant interaction between diabetes and the ACCI (HR = 0.26, 95% CI: 0.07-0.91, p = 0.03). RSF models identified age as the key predictor of OS and MGMT methylation as the main predictor of PFS, while ACCI ≥ 6 contributed only modestly (mean drop for OS: 0.025; and PFS: 0.019).
conclusionsThe ACCI showed limited and inconsistent prognostic value in elderly glioblastoma patients, while diabetes emerged as the only consistent comorbidity predictor of OS and PFS. These findings suggest that comorbidity burden may influence outcomes but underscore the need for larger studies to clarify the role of the ACCI in treatment stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.